Gyre Therapeutics (GYRE) Gross Margin (2020 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Gross Margin of 94.55% for Q1 2026, down 140.0% year-over-year from 236.38% in Q1 2025, and down 0.8% quarter-over-quarter from 95.31% in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Gross Margin (2020 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Gross Margin for 7 consecutive years, with 94.55% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 140.0% year-over-year to 94.55%; the TTM figure through Mar 2026 stood at 95.09% (down 114.0% YoY), while the FY2025 annual figure was 95.35%, down 97.0% from the prior year.
- Gross Margin declined to 94.55% in Q1 2026 per GYRE's latest filing, from 95.31% in the prior quarter.
- Across five years, Gross Margin topped out at 96.95% in Q2 2024 and bottomed at 0.5% in Q1 2022.
- Historically, Gross Margin has averaged 89.38% across 5 years, with a median of 95.78% in 2024.
- Annual changes were most pronounced in 2022 — Gross Margin surged 9823 bps — and 2025, when it sank 157 bps.
- Gyre Therapeutics' Gross Margin stood at 96.06% in 2022, then retreated by 1 bps to 95.4% in 2023, then advanced by 0 bps to 95.78% in 2024, then fell by 0 bps to 95.31% in 2025, then declined by 1 bps to 94.55% in 2026.
- Business Quant data shows GYRE's Gross Margin at 94.55% in Q1 2026, 95.31% in Q4 2025, and 94.67% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 92.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.41% |
| Mar 31, 2026 | 94.55% |
| Dec 31, 2025 | 95.31% |
| Sep 30, 2025 | 94.67% |
| Jun 30, 2025 | 86.16% |
| Mar 31, 2025 | 95.95% |
| Dec 31, 2024 | 95.78% |
| Sep 30, 2024 | 96.24% |
| Jun 30, 2024 | 96.95% |
| Mar 31, 2024 | 96.40% |
| Dec 31, 2023 | 95.40% |
| Sep 30, 2023 | 96.30% |
| Jun 30, 2023 | 96.33% |
| Mar 31, 2023 | 95.49% |
| Dec 31, 2022 | 96.06% |
| Mar 31, 2022 | -0.50% |
| Dec 31, 2021 | -0.57% |
| Sep 30, 2021 | -0.35% |
| Jun 30, 2021 | -0.62% |
| Mar 31, 2021 | -0.89% |